Phase I Study Evaluating Combination Therapy With the Receptor Tyrosine Kinase Inhibitor PLX3397 and Sirolimus in Patients With Unresectable Sarcoma and Phase II Study in Malignant Peripheral Nerve Sheath Tumors
Latest Information Update: 18 Mar 2024
At a glance
- Drugs Pexidartinib (Primary) ; Sirolimus
- Indications Angiomyolipoma; Gastrointestinal stromal tumours; Giant cell tumour of tendon sheath; Leiomyosarcoma; Meningioma; Nerve sheath neoplasms; Sarcoma; Soft tissue sarcoma
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms PLX3397
- 12 Mar 2024 Planned End Date changed from 1 Mar 2024 to 1 Jun 2024.
- 12 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 16 Feb 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Jul 2023.